B. Mills, J.W. Gray, W. Yantasee, Development of a nanoparticle-based immunotherapy targeting PD-I.1 and PLK1 for lung cancer treatment, Nat. Commun. 13 (1) (2022) 4261, https://doi.org/10.1038/s41467-022-31926-9.

[221] Q. Jin, W. Zhu, J. Zhu, J. Zhu, J. Shen, Z. Liu, Y. Yang, Q. Chen, Nanoparticle-mediated delivery of inhaled immunotherapeutics for treating lung metastasis, Adv. Mater. 33 (7) (2021) 2007557, https://doi.org/10.1002/adma.202007557.

[222] T. Nakamura, T. Sato, R. Endo, S. Sasaki, N. Takahashi, Y. Sato, M. Hyodo, Y. Hayakawa, H. Harashima, STING agonist loaded lipid nanoparticles overcome anti-PD-1 resistance in melanoma lung metastasis via NK cell activation, J. ImmunoTherapy Cancer 9 (7) (2021) e002852, https://doi.org/10.1136/jitc-2021-002852.

[223] Y. Ma, Y. Liu, Y. Zhi, H. Wang, M. Yang, J. Niu, L. Zhao, P. Wang, Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer, Cancer Nanotechnol. 13 (1) (2022) 10, https://doi.org/10.1186/s12645-022-00116-z.

[224] M.E. Levison, J.H. Levison, Pharmacokinetics and pharmacodynamics of antibacterial agents, Infect. Dis. Clin. North Am. 23 (4) (2009) 791–815, https://doi.org/10.1016/j.idc.2009.06.008, vii.

[225] X. Li, S.M. Robinson, A. Gupta, K. Saha, Z. Jiang, D.F. Moyano, A. Sahar, M. A. Riley, V.M. Rotello, Functional gold nanoparticles as potent antimicrobial agents against multi-drug-resistant bacteria, ACS Nano 8 (10) (2014) 10682–10686, https://doi.org/10.1021/nn504265.

[226] N. Chakraborty, D. Jha, I. Roy, P. Kumar, S.S. Gaurav, K. Marimuthu, O.-T. Ng, R. Lakshminarayanan, N.K. Verma, H.K. Gautam, Nanobiotics against antimicrobial resistance: harnessing the power of nanoscale materials and technologies, J. Nanobiotechnol. 20 (1) (2022) 375, https://doi.org/10.1186/s12951-022-01573-9.

[227] F. Aflakian, F. Mirzavi, H.T. Aiyelabegan, A. Soleimani, J. Gholizadeh Navashenaq, I. Karimi-Sani, A. Rafati Zomorodi, R. Vakili-Ghartavol, Nanoparticles-based therapeutics for the management of bacterial infections: a special emphasis on FDA approved products and clinical trials, Eur. J. Pharmaceut. Sci. 188 (2023) 106515, https://doi.org/10.1016/j.epps.2023.106515.

[228] H.A. Foster, I.B. Ditta, S. Varghese, A. Steele, Photocatalytic disinfection using titanium dioxide: spectrum and mechanism of antimicrobial activity, Appl. Microbiol. Biotechnol. 90 (6) (2011) 1847–1868, https://doi.org/10.1007/s00253-011-3213-7.

[229] B. Bai, S. Saranya, V. Dheepaasri, S. Muniasamy, N.S. Alharbi, B. Selvaraj, V. S. Undal, B.M. Gnanamangai, Biosynthesized copper oxide nanoparticles (CuO NPs) enhances the anti-biofilm efficacy against K. pneumoniae and S. aureus, J. King Saud Univ. Sci. 34 (6) (2022) 102120, https://doi.org/10.1016/j.jksus.2022.102120.

[230] D.P. Linklater, V.A. Baulin, X. Le Guével, J.B. Fleury, E. Hanssen, T.H.P. Nguyen, S. Juodkazis, G. Bryant, R.J. Crawford, P. Stoodley, E.P. Ivanova, Antibacterial action of nanoparticles by lethal stretching of bacterial cell membranes, Adv. Mater. 32 (52) (2020) e2005679, https://doi.org/10.1002/adma.202005679.

[231] N.Y. Lee, W.C. Ko, P.R. Hsueh, Nanoparticles in the treatment of infections caused by multidrug-resistant organisms, Front. Pharmacol. 10 (2019) 1153, https://doi.org/10.3389/fphar.2019.01153.

[232] T.M. File Jr., M.S. Niederman, Antimicrobial therapy of community-acquired pneumonia, Infect. Dis. Clin. 18 (4) (2004) 993–1016, https://doi.org/10.1016/j.idc.2004.07.011, xi.

[233] J. Singh, Ceftobiprole medocaril (Zevtera) – FDA approved antibiotic for three infections including methicillin-resistant Staphylococcus aureus, J. Mol. Chem. 4 (2) (2024) 692, https://doi.org/10.62110/scienceinc.jmc.2024.692.

[234] H. Wang, C.V. Charles, A review of newly approved antibiotic treatment for community-acquired bacterial pneumonia: Ilefamulin, Senior Care Pharmacist 35 (8) (2020) 349–354, https://doi.org/10.4140/TCP.n.2020.349.

[235] S.C. Duwe, B. Schmidt, B.C. Gärtner, J. Timm, O. Adams, H. Fickenscher, M. Schmidtke, Prophylaxis and treatment of influenza: options, antiviral susceptibility, and existing recommendations, GMS Infectious Diseases 9 (2021) Doc02, https://doi.org/10.3205/id000071.

[236] Miwako Kobayashi, A.J.L. R.G, Jennifer L. Farrar, Rebecca L. Morgan, Doug Campos-Outcalt, Robert Schechter, Katherine A. Poehling, Sarah S. Long, Jamie Loehr, Adam L. Cohen, Use of 21-valent pneumococcal conjugate vaccine among U.S. Adults: recommendations of the advisory committee on immunization Practices — United States, 2024, MMWR (Morb. Mortal. Wkly. Rep.) 73 (36) (2024) 793–798.

[237] J. Tang, Q. Ouyang, Y. Li, P. Zhang, W. Jin, S. Qu, F. Yang, Z. He, M. Qin, Nanomaterials for delivering antibiotics in the therapy of pneumonia, Int. J. Mol. Sci. 23 (2022) 15738, https://doi.org/10.3390/ijms232415738.

[238] Z. Huang, S.N. Klodzińska, F. Wan, H.M. Nielsen, Nanoparticle-mediated pulmonary drug delivery: state of the art towards efficient treatment of recalcitrant respiratory tract bacterial infections, Drug Deliv. Translational Res. 11 (4) (2021) 1634–1654, https://doi.org/10.1007/s13346-021-00954-1.

[239] J. Wang, Y. Guo, W. Lu, X. Liu, J. Zhang, J. Sun, G. Chai, Dry powder inhalation containing muco-inert ciprofloxacin and colistin co-loaded liposomes for pulmonary P. Aeruginosa biofilm eradication, Int. J. Pharm. 658 (2024) 124208, https://doi.org/10.1016/j.ijpharm.2024.124208.

[240] M. Tan, F. Reyes-Ortega, E.K. Schneider-Futschik, Successes and challenges: inhaled treatment approaches using magnetic nanoparticles in cystic fibrosis, Magnetochemistry 6 (2020) 25, https://doi.org/10.3390/magnetochemistry6020025.

[241] L. Cresti, G. Conte, G. Cappello, J. Brunetti, C. Falciani, L. Bracci, F. Quaglia, F. Ungaro, I. d'Angelo, A. Pini, Inhalable polymeric nanoparticles for pulmonary delivery of antimicrobial peptide SET-M33: antibacterial activity and toxicity in vitro and in vivo, Pharmaceutics 15 (2023) 3, https://doi.org/10.3390/ pharmaceutics15010003.

[242] Z. Jiang, S. Huo, L. Qiao, P. Lin, L. Fu, Y. Wu, W. Li, C. Bian, Y. Li, N. Li, H. Cheng, X. Nie, S. Ding, Inhalable mucin-permeable nanomicelles deliver antibiotics for effective treatment of chronic pneumonia, J. Mater. Chem. B 12 (34) (2024) 8465–8476, https://doi.org/10.1039/D3TB02970K.

[243] M.-Y. Liu, X. Liu, C.-Y. Wang, Q.-Q. Wan, Y.-F. Tian, S.-L. Liu, D.-W. Pang, Z.-G. Wang, Inhalable polymeric microparticles for phage and photothermal synergistic therapy of methicillin-resistant Staphylococcus aureus pneumonia, Nano Lett. 24 (28) (2024) 8752–8762, https://doi.org/10.1021/acs. nanolett.4c02318.

[244] M.M. Abdelaziz, A. Hefnawy, A. Anter, M.M. Abdelatif, M.A.F. Khalil, I.A. Khalil, Inhalable vancomycin-loaded lactose microparticles for treatment of MRSA pneumonia, J. Drug Deliv. Sci. Technol. 80 (2023) 104150, https://doi.org/10.1016/j.jddst.2023.104150.

[245] X. Pan, N. Wu, S. Tian, J. Guo, C. Wang, Y. Sun, Z. Huang, F. Chen, Q. Wu, Y. Jing, Z. Yin, B. Zhao, X. Xiong, H. Liu, D. Zhou, Inhalable MOF-derived nanoparticles for sonodynamic therapy of bacterial pneumonia, Adv. Funct. Mater. 32 (25) (2022) 2112145, https://doi.org/10.1002/adfm.202112145.

[246] H. Dong, Y. Zhao, S. Li, Q. Wang, M. Li, K. Zhao, Z. Zhang, J. Shi, X. Zhao, J. Liu, An inhalable nanoparticle enabling virulence factor elimination and antibiotics delivery for pneumococcal pneumonia therapy, J. Control. Release 375 (2024) 698–711, https://doi.org/10.1016/j.jconrel.2024.09.036.

[247] T. Galbadage, D. Liu, L.B. Alemany, R. Pal, J.M. Tour, R.S. Gunasekera, J. D. Cirillo, Molecular nanomachines disrupt cell wall, increasing sensitivity of extensively drug-resistant Klebsiella pneumoniae to meropenem, ACS Nano 13 (12) (2019) 14377–14387, https://doi.org/10.1021/ acsnano.9b07836.

[248] P.V. Gupta, A.M. Nirwane, M.S. Nagarsenker, Inhalable levofloxacin liposomes complemented with lysozyme for treatment of pulmonary infection in rats: effective antimicrobial and antibiofilm strategy, AAPS PharmSciTech 19 (3) (2018) 1454–1467, https://doi.org/10.1208/s12249-017-0945-4.

[249] V.S. Gondil, K. Harjai, S. Chhibber, Investigating the potential of endolysin loaded chitosan nanoparticles in the treatment of pneumococcal pneumonia, J. Drug Deliv. Sci. Technol. 61 (2021) 102142, https://doi.org/10.1016/j.jddst.2020.102142.

[250] W. Muhammad, Y. Zhang, J. Zhu, J. Xie, S. Wang, R. Wang, B. Feng, J. Zhou, W. Chen, Y. Xu, Q. Yao, Y. Yu, H. Cao, C. Gao, Co-delivery of azithromycin and ibuprofen by ROS-responsive polymer nanoparticles synergistically attenuates the acute lung injury, Biomater. Adv. 154 (2023) 213621, https://doi.org/10.1016/j. bioadv.2023.213621.

[251] P. Zhang, Q. Ouyang, T. Zhai, J. Sun, J. Wu, F. Qin, N. Zhang, S. Yue, X. Yang, H. Zhang, Y. Hou, L. Deng, F. Wang, Q. Zhan, Q. Yu, M. Qin, Z. Gan, An inflammation-targeted nanoparticle with bacteria forced release of polymyxin B for pneumonia therapy, Nanoscale 14 (41) (2022) 15291–15304, https://doi.org/10.1039/d2nr02026b.

[252] Q. Ma, C. Yao, H. Shi, J. Xu, H. Dai, Z. Fei, Y. Wu, T. Lu, C. Wang, Targeted delivery of dexamethasone in acute pneumonia, Biomater. Sci. 9 (16) (2021) 5569–5576, https://doi.org/10.1039/d1bm00924a.

[253] R. Li, H. Gao, R. Zhang, B. Zhang, X. Wang, X. Zhang, R. Li, Biocompatible formulation of a hydrophobic antimicrobial peptide L30 through nanotechnology principles and its potential role in mouse pneumonia model infected with Staphylococcus aureus, Colloids Surf. B Biointerfaces 236 (2024) 113823, https://doi.org/10.1016/j.colsurf.2024.113823.

[254] W. Zhong, Y. Fu, X. Liao, N. Xu, L. Shen, J. Wu, D. Zheng, Y. Zhou, L. Tan, B. Xia, X. Fan, M. Zhou, Y. Yao, C. Yang, Enhancing safe and effective treatment of carbapenem-resistant Klebsiella pneumoniae with polymyxin B-loaded dendritic nanoparticles, Chem. Eng. J. 498 (2024) 155753, https://doi.org/10.1016/j. cej.2024.155753.

[255] J. Liu, X. Chen, L. Xu, F. Tu, X. Rui, L. Zhang, Z. Yan, Y. Liu, R. Hu, Neutrophil membrane-coated nanoparticles exhibit increased antimicrobial activity in an anti-microbial resistant K. pneumonia infection model, Nanomed. Nanotechnol. Biol. Med. 48 (2023) 102640, https://doi.org/10.1016/j.nano.2022.102640.

[256] S. Ghorai, H. Shand, S. Patra, K. Panda, M.J. Santiago, M.S. Rahman, S. Chinnapaiyan, H.J. Unwalla, Nanomedicine for the treatment of viral diseases: smaller solution to bigger problems, Pharmaceutics 16 (3) (2024) 407, https://doi.org/10.3390/pharmaceutics16030407.

[257] C. Chang, C. Lu, Y. Zheng, J. Ji, L. Lin, L. Chen, Z. Chen, R. Chen, Sonication-assisted self-assembled resveratrol nanoparticles with enhanced antiviral and anti-inflammatory activity against respiratory syncytial virus-induced pneumonia, ACS Appl. Mater. Interfaces 16 (38) (2024) 50442–50458, https://doi.org/10.1021/acsmi.4c11525.

[258] X. Lv, J. Min, J. Huang, H. Wang, S. Wei, C. Huang, J. Dai, Z. Chen, H. Zhou, Y. Xu, H. Zhao, Z. Liu, J. Wang, Simultaneously controlling inflammation and infection by smart nanomedicine responding to the inflammatory microenvironment, Adv. Sci. (2024) 2403934, https://doi.org/10.1002/advs.202403934.

[259] K. Ohashi, T. Kabasawa, T. Ozeki, H. Okada, One-step preparation of rifampicin/ poly(lactic-co-glycolic acid) nanoparticle-containing mannitol microspheres using a four-fluid nozzle spray drier for inhalation therapy of tuberculosis, J. Control. Release 135 (1) (2009) 19–24, https://doi.org/10.1016/j.jconrel.2008.11.027.

[260] R. Pandey, A. Zahoor, S. Sharma, G.K. Khuller, Nanoparticle encapsulated antitubercular drugs as a potential oral drug delivery system against murine tuberculosis, Tuberculosis 83 (6) (2003) 373–378, https://doi.org/10.1016/j. tube.2003.07.001.
[261] J. Wu, T. Zhai, J. Sun, Q. Yu, Y. Feng, R. Li, H. Wang, Q. Ouyang, T. Yang, Q. Zhan, L. Deng, M. Qin, F. Wang, Mucus-permeable polymyxin B-hyaluronic acid/poly (lactic-co-glycolic acid) nanoparticle platform for the nebulized treatment of lung infections, J. Colloid Interface Sci. 624 (2022) 307-319, https://doi.org/10.1016/j.jcis.2022.05.121.

[262] F. Anversa Dimer, C. de Souza Carvalho-Wodarz, A. Goes, K. Cirnski, J. Herrmann, V. Schmitt, L. Pätzold, N. Abed, C. De Rossi, M. Bischoff, P. Couvreur, R. Müller, C.-M. Lehr, PLGA nanocapsules improve the delivery of clarithromycin to kill intracellular Staphylococcus aureus and Mycobacterium abscessus, Nanomed. Nanotechnol. Biol. Med. 24 (2020) 102125, https://doi.org/10.1016/j.nano.2019.102125.

[263] B. Casciaro, I. d'Angelo, X. Zhang, M. R. Loffredo, G. Conte, F. Cappiole, F. Quaglia, Y.-P.P. Di, F. Ungaro, M.L. Mangoni, Poly(lactide-co-glycolide) nanoparticles for prolonged therapeutic efficacy of esculentin-1a-derived antimicrobial peptides against Pseudomonas aeruginosa lung infection: in vitro and in vivo studies, Biomacromolecules 20 (5) (2019) 1876-1888, https://doi.org/10.1021/acs.biomac.8b01829.

[264] M.Z.R. Sabuj, T. Dargaville, L. Nissen, N. Islam, Inhaled ciprofloxacin-loaded poly(2-ethyl-2-oxazoline) nanoparticles from dry powder inhaler formulation for the potential treatment of lower respiratory tract infections, PLoS One 16 (12) (2021) e0261720, https://doi.org/10.1371/journal.pone.0261720.

[265] J. Zhang, F. Leifer, S. Rose, D.Y. Chun, J. Thaisz, T. Herr, M. Nashed, J. Joseph, W. R. Perkins, K. DiPetrillo, Amikacin liposome inhalation suspension (ALIS) penetrates non-tuberous mycobacterial biofilms and enhances amikacin uptake into macrophages, Front. Microbiol. 9 (2018) 915, https://doi.org/10.3389/fmicb.2018.00915.

[266] V. Viswanathan, R. Parande, A. Bhanalikar, P. Gupta, U. Gupta, A. Mukne, Inhalable liposomes of Glycyrrhiza glabra extract for use in tuberculosis: formulation, in vitro characterization, in vivo lung deposition, and in vivo pharmacodynamic studies, Drug Dev. Ind. Pharm. 45 (1) (2019) 11-20, https://doi.org/10.1080/03639045.2018.1513025.

[267] J.F. Marier, J.L. Brazier, J. Lavigne, M.P. Ducharme, Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats, J. Antimicrob. Chemother. 52 (2) (2003) 247-252, https://doi.org/10.1093/jac/dkg317.

[268] M. Bassetti, A. Vena, A. Russo, M. Peghin, Inhaled liposomal antimicrobial delivery in lung infections, Drugs 80 (13) (2020) 1309-1318, https://doi.org/10.1007/s40265-020-01359-z.

[269] D. Thiyagarajan, B. Huck, B. Nothdurft, M. Koch, D. Rudolph, M. Rutschmann, C. Feldmann, C. Hozsa, M. Furch, K.F.W. Besecke, R.K. Gieseler, B. Loretz, C.-M. Lehr, Spray-dried lactose-leucine microparticles for pulmonary delivery of antimycobacterial nanopharmaceuticals, Drug Deliv. Translational Res. 11 (4) (2021) 1766-1778, https://doi.org/10.1007/s13346-020-01101-7.

[270] R.N. Jahan, Z. Khan, M.S. Akhtar, M.D. Ansari, P. Solanki, F.J. Ahmad, M. Agil, Y. Sultana, Development of bedaquiline-loaded SNEDDS using quality by design (QbD) approach to improve biopharmaceutical attributes for the management of multidrug-resistant tuberculosis (MDR-TB), Antibiotics (Basel) 12 (10) (2023) 1510, https://doi.org/10.3390/antibiotics1210150.

[271] C.S. Haworth, J.E. Poweraker, P. Wilkinson, R.F. Kenyon, D. Bilton, Inhaled colistin in patients with bronchiectasis and chronic Pseudomonas aeruginosa infection, Am. J. Respir. Crit. Care Med. 189 (8) (2014) 975-982, https://doi.org/10.1164/rccm.201312-22080C.

[272] C. Falciani, F. Zevolini, J. Brunetti, G. Riolo, R. Gracia, M. Marradi, I. Loinaz, C. Ziemann, U. Cossio, J. Llop, L. Bracci, A. Pini, Antimicrobial peptide-loaded nanoparticles as inhalation therapy for Pseudomonas aeruginosa infections, Int. J. Nanomed. 15 (2020) 1117-1128, https://doi.org/10.2147/ijm.S218966.

[273] D.P. Gaspar, M.M. Gaspar, C.V. Eleutério, A. Grenha, M. Blanco, L.M. Gonçalves, P. Taboada, A.J. Meida, C. Remunán-López, Microuencapsulated solid lipid nanoparticles as a hybrid platform for pulmonary antibiotic delivery, Mol. Pharm. 14 (9) (2017) 2977-2990, https://doi.org/10.1021/acs.molpharmaceut.7b00169.

[274] P.K. Paul, T. Nakpheng, H. Paliwal, K. Prem Ananth, T. Srichana, Inhalable solid lipid nanoparticles of levofloxacin for potential tuberculosis treatment, Int. J. Pharm. 660 (2024) 124309, https://doi.org/10.1016/j.ijpharm.2024.124309.

[275] B.D. Ulery, D. Kumar, A.E. Ramer-Tait, D.W. Metzger, M.J. Wannemuehler, B. Narasimhan, Design of a protective single-dose intranasal nanoparticle-based vaccine platform for respiratory infectious diseases, PLoS One 6 (3) (2011) e17642, https://doi.org/10.1371/journal.pone.0017642.

[276] D. Huo, J. Ding, Y.X. Cui, L.Y. Xia, H. Li, J. He, Z.Y. Zhou, H.W. Wang, Y. Hu, X-ray CT and pneumonia inhibition properties of gold-silver nanoparticles for targeting MRSA induced pneumonia, Biomaterials 35 (25) (2014) 7032-7041, https://doi.org/10.1016/j.biomaterials.2014.04.092.

[277] N. Changsan, C. Sinsuepboi, Dry powder inhalation formulation of chitosan nanoparticles for co-administration of isoniazid and pyrazinamide, Pharmaceut. Dev. Technol. 26 (2) (2021) 181-192, https://doi.org/10.1080/10837450.2020.1852570.

[278] J. Xu, W. Dai, Z. Wang, B. Chen, Z. Li, X. Fan, Intranasal vaccination with chitosan-DNA nanoparticles expressing pneumococcal surface antigen A protects mice against nasopharyngeal colonization by Streptococcus pneumoniae, Clin. Vaccine Immunol. 18 (1) (2011) 75-81, https://doi.org/10.1012/CVI.00263-10.

[279] M. Shirley, Amikacin liposome inhalation suspension: a review in Mycobacterium avium complex lung disease, Drugs 79 (5) (2019) 555-562, https://doi.org/10.1007/s40265-019-01095-z.

[280] B.C. Huck, D. Thiyagarajan, A. Bali, A. Boese, K.F.W. Besecke, C. Hozsa, R. K. Gieseler, M. Furch, C. Carvalho-Wodarz, F. Waldow, D. Schwudke, O. Metelkina, A. Titz, H. Huwer, K. Schwarzkopf, J. Hoppsädtär, A.K. Kiemer, M. Koch, B. Loretz, C.-M. Lehr, Nano-in-Microparticles for aerosol delivery of antibiotic-loaded, fucose-derivatized, and macrophage-targeted liposomes to combat mycobacterial infections: in vitro deposition, pulmonary barrier interactions, and targeted delivery, Adv. Healthcare Mater. 11 (11) (2022) 2102117, https://doi.org/10.1002/adhm.202102117.

[281] V. Puri, K.R. Chaudhary, A. Singh, C. Singh, Inhalation potential of N-Acetylcysteine loaded PLGA nanoparticles for the management of tuberculosis: in vitro lung deposition and efficacy studies, Curr. Res. Pharmacol. Drug Discovery 3 (2022) 100084, https://doi.org/10.1016/j.crphar.2022.100084.

[282] S. Shah, D. Cristopher, S. Sharma, M. Soniwala, J. Chavda, Inhalable linezolid loaded PLGA nanoparticles for treatment of tuberculosis: design, development and in vitro evaluation, J. Drug Deliv. Sci. Technol. 60 (2020) 102013, https://doi.org/10.1016/j.jddst.2020.102013.

[283] M. Dhayalan, W. Wang, S.U.M. Riyaz, R.A. Dinesh, J. Shanmugam, S. S. Irudayaraj, A. Stalin, J. Giri, S. Mallik, R. Hu, Advances in functional lipid nanoparticles: from drug delivery platforms to clinical applications, 3 Biotech 14 (2) (2024) 57, https://doi.org/10.1007/s13205-023-03901-8.

[284] Q. Wan, X. Zhang, D. Zhou, R. Xie, Y. Cai, K. Zhang, X. Sun, Inhaled nano-based therapeutics for pulmonary fibrosis: recent advances and future prospects, J. Nanobiotechnol. 21 (1) (2023) 215, https://doi.org/10.1186/s12951-023-01971-9.

[285] E.Z. Dahmash, D.K. Ali, H.S. Alyami, H. AbdulKarim, M.H. Alyami, A.H. Aodah, Novel thymoquinone nanoparticles using poly(ester amide) based on L-arginine-targeting pulmonary drug delivery, Polymers 14 (6) (2022) 1082, https://doi.org/10.3390/polym14061082.

[286] H. Jin, Z. Zhao, Q. Lan, H. Zhou, Z. Mai, Y. Wang, X. Ding, W. Zhang, J. Pi, C. E. Evans, X. Liu, Nasal delivery of hesperidin/chitosan nanoparticles suppresses cytokine storm syndrome in a mouse model of acute lung injury, Front. Pharmacol. 11 (2020) 592238, https://doi.org/10.3389/fphar.2020.592238.

[287] X. Huang, E. Kon, X. Han, X. Zhang, N. Kong, M.J. Mitchell, D. Peer, W. Tao, Nanotechnology-based strategies against SARS-CoV-2 variants, Nat. Nanotechnol. 17 (10) (2022) 1027-1037, https://doi.org/10.1038/s41565-022-01174-5.

[288] B. Surnar, M.Z. Kamran, A.S. Shah, S. Dhar, Clinically approved antiviral drug in an orally administrable nanoparticle for COVID-19, ACS Pharmacol. Transl. Sci. 3 (6) (2020) 1371-1380, https://doi.org/10.1021/acspstc10c00179.

[289] C. Li, W. Wang, W. Song, Z. Zhao, Q. Tan, Z. Zhao, L. Tang, Z. Zhu, J. Yin, J. Bai, X. Dong, S. Tan, Q. Hu, B.Z. Tang, X. Huang, Antiviral and anti-inflammatory treatment with multifunctional alveolar macrophage-like nanoparticles in a surrogate mouse model of COVID-19, Adv. Sci. 8 (13) (2021) 2003556, https://doi.org/10.1002/advs.202003556.

[290] T.R. Martin, Cytokines and the acute respiratory distress syndrome (ARDS): a question of balance, Nat. Med. 3 (3) (1997) 272-273, https://doi.org/10.1038/nm03972.

[291] Q. Ye, B. Wang, J. Mao, The pathogenesis and treatment of the 'Cytokine Storm' in COVID-19, J. Infect. 80 (6) (2020) 607-613, https://doi.org/10.1016/j.jinf.2020.03.037.

[292] C. Wu, X. Chen, Y. Cai, J. Xia, X. Zhou, S. Xu, H. Huang, L. Zhang, X. Zhou, C. Du, Y. Zhang, J. Song, S. Wang, Y. Chao, Z. Yang, J. Xu, X. Zhou, D. Chen, W. Xiong, L. Xu, F. Zhou, J. Jiang, C. Bai, J. Zheng, Y. Song, Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China JAMA Int. Med. 180 (7) (2020) 934-943, https://doi.org/10.1001/jamainternmed.2020.0994.

[293] S. Chen, E. Chen, X. Guan, J. Li, A. Qin, C. Wang, X. Fu, C. Huang, J. Li, Y. Tang, M. Wei, L. Zhang, J. Su, Magnetically controlled nanorobots induced oriented and rapid clearance of the cytokine storm for acute lung injury therapy, Colloids Surf. B Biointerfaces 234 (2024) 113731, https://doi.org/10.1016/j.colsurf.2023.113731.

[294] H. Wang, Y. Jiao, S. Ma, Z. Li, J. Gong, Q. Jiang, Y. Shang, H. Li, J. Li, N. Li, R. C. Zhao, B. Ding, Nebulized inhalation of peptide-modified DNA origami to alleviate acute lung injury, Nano Lett. 24 (20) (2024) 6102-6111, https://doi.org/10.1021/acs.nanolett.4c01222.

[295] N. Batool, S. Yoon, S. Imdad, M. Kong, H. Kim, S. Ryu, J.H. Lee, A.K. Chaurasia, K. Kim, An antibacterial nanorobotic approach for the specific targeting and removal of multiple drug-resistant Staphylococcus aureus, Small 17 (20) (2021) 2100257, https://doi.org/10.1002/small.202100257.

[296] L. Yue, C. Gao, J. Li, H. Chen, S.M.Y. Lee, R. Luo, R. Wang, Chemotaxis-guided self-propelled macrophage motor for targeted treatment of acute pneumonia, Adv. Mater. 35 (20) (2023) 2211626, https://doi.org/10.1002/adma.202211626.

[297] A.C. Anselmo, V. Gupta, B.J. Zern, D. Pan, M. Zakrewsky, V. Muzykantov, S. Mitragotri, Delivering nanoparticles to lungs while avoiding liver and spleen through adsorption on red blood cells, ACS Nano 7 (12) (2013) 11129-11137, https://doi.org/10.1021/nn404853z.

[298] Y. Li, C. Guo, Q. Chen, Y. Su, H. Guo, R. Liu, C. Sun, S. Mi, J. Wang, D. Chen, Improvement of pneumonia by curcumin-loaded bionomosomes based on platycodon grandiflorum polysaccharides via calming cytokine storm, Int. J. Biol. Macromol. 202 (2022) 691-706, https://doi.org/10.1016/j.ijbiomac.2022.01.194.

[299] J. Kim, C.C. Mayorga-Martinez, J. Vyskočil, D. Ruzek, M. Pumera, Plasmonic-magnetic nanorobots for SARS-CoV-2 RNA detection through electronic readout, Appl. Mater. Today 27 (2022) 101402, https://doi.org/10.1016/j.apmt.2022.101402.

[300] C.C. Mayorga-Martinez, J. Vyskočil, F. Novotný, P. Bednar, D. Ruzek, O. Alduhaish, M. Pumera, Collective behavior of magnetic microrobots through immuno-sandwich assay: on-the-fly COVID-19 sensing, Appl. Mater. Today 26 (2022) 101337, https://doi.org/10.1016/j.apmt.2021.101337.
[301] R. Li, Y. Zhao, H. Fan, M. Chen, W. Hu, Q. Zhang, M. Jin, G.L. Liu, L. Huang, Versatile nanorobot hand biosensor for specific capture and ultrasensitive quantification of viral nanoparticles, Mater. Today Bio 16 (2022) 100444, https://doi.org/10.1016/j.mtbio.2022.100444.

[302] H. Sakai, M. Horiguchi, C. Ozawa, T. Akita, K. Hirota, K. Shudo, H. Terada, K. Makino, H. Kubo, C. Yamashita, Pulmonary administration of Am80 regenerates collapsed alveoli, J. Control. Release 196 (2014) 154–160, https://doi.org/10.1016/j.jconrel.2014.10.004.

[303] T. Akita, K. Oda, S. Narukawa, Y. Morita, K. Tange, Y. Nakai, C. Yamashita, Intracellular drug delivery process of Am80-encapsulated lipid nanoparticles aiming for alveolar regeneration, Pharmaceuticals 16 (6) (2023) 838, https://doi.org/10.3390/ph16060838.

[304] T. Mkorombindo, M.T. Dransfield, Inhaled corticosteroids in chronic obstructive pulmonary disease: benefits and risks, Clin. Chest Med. 41 (3) (2020) 475–484, https://doi.org/10.1016/j.ccm.2020.05.006.

[305] M.E. Taghavizadeh Yazdi, M. Qayoomian, S. Beigoli, M.H. Boskabady, Recent advances in nanoparticle applications in respiratory disorders: a review, Front. Pharmacol. 14 (2023) 1059343, https://doi.org/10.3389/fphar.2023.1059343.

[306] K. Bohne Japiassu, F. Fay, A. Marengo, S.A. Mendanha, C. Cailleau, Y. Louguenouni, Q. Wang, S. Denis, N. Tsapis, T. Leite Nascimento, E. Martins Lima, E. Fattal, Hyaluronic acid-conjugated liposomes loaded with dexamethasone: a promising approach for the treatment of inflammatory diseases, Int. J. Pharm. 639 (2023) 122946, https://doi.org/10.1016/j.ijpharm.2023.122946.

[307] C. Puricelli, C.L. Gigliotti, I. Stoppa, S. Sacchetti, D. Pantham, A. Scomparin, R. Rolla, S. Pizzimenti, U. Dianzani, E. Boggio, S. Sutti, Use of poly lactic-co-glycolic acid nano and micro particles in the delivery of drugs modulating different phases of inflammation, Pharmaceuticals 15 (6) (2023) 1772, https://doi.org/10.3390/pharmaceutics15061772.

[308] P.J. Barnes, Theophylline, Pharmaceuticals 3 (3) (2010) 725–747, https://doi.org/10.3390/ph3030725.

[309] M.D. Buhecha, A.B. Lansley, S. Somavarapu, A.S. Pannala, Development and characterization of PLA nanoparticles for pulmonary drug delivery: Co-encapsulation of theophylline and besudoneide, a hydrophilic and lipophilic drug, J. Drug Deliv. Sci. Technol. 53 (2019) 101128, https://doi.org/10.1016/j.jddst.2019.101128.

[310] G. Hodge, V. Mukaro, P.N. Reynolds, S. Hodge, Role of increased CD8/CD28null T cells and alternative co-stimulatory molecules in chronic obstructive pulmonary disease, Clin. Exp. Immunol. 166 (1) (2011) 94–102, https://doi.org/10.1111/j.1365-2249.2011.04455.x.

[311] K. Chikuma, K. Arima, Y. Asaba, R. Kubota, S. Asayama, K. Sato, H. Kawakami, The potential of lipid-polymer nanoparticles as epigenetic and ROS control approaches for COPD, Free Radic. Res. 54 (11–12) (2020) 829–840, https://doi.org/10.1080/10715762.2019.1696965.

[312] X. Chen, D. Wang, X. Guo, X. Li, W. Ye, Y. Qi, W. Gu, Curcumin-loaded mPEG-PLGA nanoparticles attenuates the apoptosis and corticosteroid resistance induced by cigarette smoke extract, Front. Pharmacol. 13 (2022) 824652, https://doi.org/10.3389/fphar.2022.824652.

[313] A. Frede, B. Neuhaus, T. Knuschke, M. Wadwa, S. Kollenda, R. Klopfleisch, W. Hansen, J. Buer, D. Bruder, M. Epple, A.M. Westendorf, Local delivery of siRNA-loaded calcium phosphate nanoparticles abates pulmonary inflammation, Nanomed. Nanotechnol. Med. Biol. Med. 13 (8) (2017) 2395–2403, https://doi.org/10.1016/j.nano.2017.08.001.

[314] E.F. Craparo, S.E. Drago, G. Costabile, M. Ferraro, E. Pace, R. Scaffaro, F. Ungaro, G. Cavallaro, Sustained-release powders based on polymer particles for pulmonary delivery of beclomethasone dipropionate in the treatment of lung inflammation, Pharmaceuticals 15 (2023) 1248, https://doi.org/10.3390/pharmaceutics15041248.

[315] J.A. Jurcisek, K.L. Brockman, L.A. Novotny, S.D. Goodman, L.O. Bakaletz, Nontypeable Haemophilus influenzae releases DNA and DNABII proteins via a T4SS-like complex and ComE of the type IV pilus machinery, Proc. Nat. Acad. Sci. USA 114 (32) (2017) E6632–e6641, https://doi.org/10.1073/pnas.1705508114.

[316] L. Martínez-Solano, M.D. Macia, A. Fajardo, A. Oliver, J.L. Martinez, Chronic Pseudomonas aeruginosa infection in chronic obstructive pulmonary disease, Clin. Infect. Dis. 47 (12) (2008) 1526–1533, https://doi.org/10.1086/593186.

[317] J. Zhu, X. Li, Y. Zhou, C. Ge, X. Li, M. Hou, Y. Wei, Y. Chen, K.W. Leong, L. Yin, Inhaled immunoantibiotics for the treatment of chronic obstructive pulmonary disease, Sci. Adv. 10 (6) (2024), https://doi.org/10.1126/sciadv.abd7904 p. eabd7904 eabd7904.

[318] A. García-Fernández, F. Sancenón, R. Martínez-Máñez, Mesoporous silica nanoparticles for pulmonary drug delivery, Adv. Drug Deliv. Rev. 177 (2021) 113953, https://doi.org/10.1016/jaddr.2021.113953.

[319] R. Patel, S.A. Naqvi, C. Griffiths, C.I. Bloom, Systemic adverse effects from inhaled corticosteroid use in asthma: a systematic review, BMJ Open Resp. Res. 7 (1) (2020) e000756, https://doi.org/10.1136/bmjresp-2020-000756.

[320] D. Ukena, L. Fishman, W.B. Niebling, Bronchial asthma: diagnosis and long-term treatment in adults, Deutsches Ärzteblatt International 105 (21) (2008) 385–394, https://doi.org/10.3238/artztebl.2008.0385.

[321] X. Zuo, Y. Gu, X. Guo, W. Zheng, H. Zheng, Y. An, C. Xu, F. Wang, Preparation of besudoneide-loaded liposomal nanoparticles for pulmonary delivery and their therapeutic effect in OVA-induced asthma in mice, Int. J. Nanomed. 19 (2024) 673–688, https://doi.org/10.2147/LN.S441345.

[322] B. Volovitz, Inhaled besudoneide in the management of acute worsenings and exacerbations of asthma: a review of the evidence, Respir. Med. 101 (4) (2007) 685–695, https://doi.org/10.1016/j.rmed.2006.10.009.

[323] M. Pozzoli, P. Rogueda, B. Zhu, T. Smith, P.M. Young, D. Traini, F. Sonvico, Dry powder nasal drug delivery: challenges, opportunities and a study of the commercial Tejinj Puvlizer Rhinocort device and formulation, Drug Dev. Ind. Pharm. 42 (10) (2016) 1660–1668, https://doi.org/10.3109/03639045.2016.1160110.

[324] Y. Yu, M. Ni, Y. Zheng, Y. Huang, Airway epithelial-targeted nanoparticle reverses asthma in inhalation therapy, J. Control. Release 367 (2024) 223–234, https://doi.org/10.1016/j.jconrel.2024.01.044.

[325] C. Rhv, H. Li, H. Cui, Q. Bi, M. Wang, Solid lipid nanoparticle delivery of rhynchophylline enhanced the efficiency of allergic asthma treatment via the upregulation of suppressor of cytokine signaling 1 by repressing the p38 signaling pathway, Bioengineered 12 (1) (2021) 8635–8649, https://doi.org/10.1080/21655979.2021.1988364.

[326] M. Zhang, H. Jiang, L. Wu, H. Lu, H. Bera, X. Zhao, X. Guo, X. Liu, D. Cun, M. Yang, Airway epithelial cell-specific delivery of lipid nanoparticles loading siRNA for asthma treatment, J. Control. Release 352 (2022) 422–437, https://doi.org/10.1016/j.jconrel.2022.10.020.

[327] A. Harugade, A.P. Sherje, A. Pethe, Chitosan: a review on properties, biological activities and recent progress in biomedical applications, React. Funct. Polym. 191 (2023) 105634, https://doi.org/10.1016/j.reactfunctpolym.2023.105634.

[328] W. Yang, Z. Dong, Y. Li, Y. Zhang, H. Fu, Y. Xie, Therapeutic efficacy of chitosan nanoparticles loaded with BCG-polysaccharide nucleic acid and ovalbumin on airway inflammation in asthmatic mice, Eur. J. Clin. Microbiol. Infect. Dis. 40 (8) (2021) 1623–1631, https://doi.org/10.1007/s10096-021-04183-9.

[329] Y. Lv, J. Zhang, C. Wang, Self-assembled chitosan nanoparticles for intranasal delivery of recombinant protein interleukin-17 receptor C (IL-17RC): preparation and evaluation in asthma mice, Bioengineered 12 (1) (2021) 3029–3039, https://doi.org/10.1080/21655979.2021.1940622.

[330] D. Zhao, D. Li, X. Cheng, Z. Zou, X. Chen, C. He, Mucoadhesive, antibacterial, and reductive nanogels as a mucolytic agent for efficient nebulized therapy to combat allergic asthma, ACS Nano 16 (7) (2022) 11161–11173, https://doi.org/10.1021/acsnano.2c03993.

[331] F.A. Oyarzun-Ampuero, J. Brea, M.I. Loza, M.J. Alonso, D. Torres, A potential nanomedicine consisting of heparin-loaded polysaccharide nanocarriers for the treatment of asthma, Macromol. Biosci. 12 (2) (2012) 176–183, https://doi.org/10.1002/mabi.201100102.

[332] D. Teijeiro-Osorio, C. Remuñán-López, M.J. Alonso, Chitosan/cyclodextrin nanoparticles can efficiently transfect the airway epithelium in vitro, Eur. J. Pharm. Biopharm. 71 (2) (2009) 257–263, https://doi.org/10.1016/j.ejpb.2008.09.020.

[333] R. Ashmawy, A. Zaki, A. Baess, I. El Sayed, Efficacy and safety of inhaled heparin in asthmatic and chronic obstructive pulmonary disease patients: a systematic review and a meta-analysis, Sci. Rep. 13 (1) (2023) 13326, https://doi.org/10.1038/s41598-023-04089-8.

[334] T. Ahmed, J. Garrigo, I. Danta, Preventing bronchoconstriction in exercise-induced asthma with inhaled heparin, N. Engl. J. Med. 329 (2) (1993) 90–95, https://doi.org/10.1056/nejm199307083290204.

[335] J. Garrigo, I. Danta, T. Ahmed, Time course of the protective effect of inhaled heparin on exercise-induced asthma, Am. J. Respir. Crit. Care Med. 153 (5) (1996) 1702–1707, https://doi.org/10.1164/ajrccm.153.5.8630624.

[336] H. Jin, J. Li, M. Zhang, R. Luo, P. Lu, W. Zhang, J. Zhang, J. Pi, W. Zheng, Z. Mai, X. Ding, X. Liu, S. Ouyang, G. Huang, Berberine-loaded biomimetic nanoparticles attenuate inflammation of experimental allergic asthma via enhancing IL-12 expression, Front. Pharmacol. 12 (2021) 724525, https://doi.org/10.3389/fphar.2021.724525.

[337] X. Zuo, X. Guo, Y. Gu, H. Zheng, Z. Zhou, X. Wang, S. Jiang, G. Wang, C. Xu, F. Wang, Recent advances in nanomaterials for asthma treatment, Int. J. Mol. Sci. 23 (22) (2022) 14427, https://doi.org/10.3390/ijms232214427.

[338] W. Wei, X. Li, R. Bi, X. Zhang, M. Zhong, H. Yang, Y. Zhang, K. Lv, Exosome membrane-modified M2 macrophages targeted nanomedicine: treatment for allergic asthma, J. Control. Release 338 (2021) 253–267, https://doi.org/10.1016/j.jconrel.2021.08.024.

[339] B.W. Ebeed, I.A. Abdelmawgood, M.A. Kotb, N.A. Mahana, A.S. Mohamed, M. A. Ramadan, A.M. Badr, M. Nasr, O.M. Qurani, R.M. Hamdy, N.Y.A. El-Hakiem, M.K. Fahim, M.M. Fekry, J.I. Eid, β-glucan nanoparticles alleviate acute asthma by suppressing ferroptosis and DNA damage in mice, Apoptosis 02013–9 (2024), https://doi.org/10.1007/s10495-024-02013-9, 02013-9.

[340] L. Rubio, B. Annangi, L. Vila, A. Hernández, R. Marcos, Antioxidant and angiogenotoxic properties of cerium oxide nanoparticles in a pulmonary-like cell system, Arch. Toxicol. 90 (2) (2016) 269–278, https://doi.org/10.1007/s00204-015-1468-7.

[341] C. Velino, F. Carella, A. Adamiano, M. Sanguinetti, A. Vitali, D. Catalucci, F. Bugli, M. Iafisco, Nanomedicine approaches for the pulmonary treatment of cystic fibrosis, Front. Bioeng. Biotechnol. 7 (2019) 406, https://doi.org/10.3389/fbioe.2019.00406.

[342] E. Robinson, K.D. MacDonald, K. Slaughter, M. McKinney, S. Patel, C. Sun, G. Sahay, Lipid nanoparticle-delivered chemically modified mRNA restores chloride secretion in cystic fibrosis, Mol. Ther. 26 (8) (2018) 2034–2046, https://doi.org/10.1016/j.jymthe.2018.05.014.

[343] S.M. Rowe, J.B. Zuckerman, D. Dorgan, J. Lascano, K. McCoy, M. Jain, M. S. Schechter, S. Lommatzsch, V. Indihar, N. Lechtzin, K. McBennett, C. Callison, B. Brown, T.G. Liou, K.D. MacDonald, S.Z. Nasr, S. Bodie, M. Vaughn, E. B. Meltzer, A.J. Barbier, Inhaled mRNA therapy for treatment of cystic fibrosis: interim results of a randomized, double-blind, placebo-controlled phase 1/2 clinical study, J. Cyst. Fibros. 22 (4) (2023) 656–664, https://doi.org/10.1016/j.jcf.2023.04.008.
[344] M.W. Konstan, P.B. Davis, J.S. Wagener, K.A. Hilliard, R.C. Stern, L.J. Milgram, T. H. Kowalczyk, S.L. Hyatt, T.L. Fink, C.R. Gedeon, S.M. Oette, J.M. Payne, O. Muhammad, A.G. Ziady, R.C. Moen, M.J. Cooper, Compacted DNA nanoparticles administered to the nasal mucosa of cystic fibrosis subjects are safe and demonstrate partial to complete cystic fibrosis transmembrane regulator reconstitution, Hum. Gene Ther. 15 (12) (2004) 1255-1269, https://doi.org/10.1089/hum.2004.15.1255.

[345] S. Rano, A. Bhaduri, M. Singh, Nanoparticle-based platforms for targeted drug delivery to the pulmonary system as therapeutics to curb cystic fibrosis: a review, J. Microbiol. Methods 217-218 (2024) 106876, https://doi.org/10.1016/j.mimet.2023.106876.

[346] D.Y. Cho, N.J. Rivers, D.-J. Lim, S. Zhang, D. Skinner, L. Yang, A.J. Menon, O. J. Kelly, M.P. Jones, B.T. Bicknell, J.W. Grayson, E. Harris, S.M. Rowe, B. A. Woodworth, Glutathione and bicarbonate nanoparticles improve mucociliary transport in cystic fibrosis epithelia, Int. Forum Allergy & Rhinology 14 (6) (2024) 1026-1035, https://doi.org/10.1002/airr.23301.

[347] B. Qiu, D. Manzanares, Y. Li, X. Wang, Z. Li, S. Terreau, Z. He, J. Lyu, W. Wang, I. Lara-Sáez, Highly branched poly β-amino ester/CpG-depleted CFTR plasmid nanoparticles for non-viral gene therapy in lung cystic fibrosis disease, Molecular Therapy Methods & Clinical Development 32 (3) (2024) 101292, https://doi.org/10.1016/j.ontm.2024.101292.

[348] W. Wang, R. Zhu, Q. Xie, A. Li, Y. Xiao, K. Li, H. Liu, D. Cui, Y. Chen, S. Wang, Enhanced bioavailability and efficiency of curcumin for the treatment of asthma by its formulation in solid lipid nanoparticles, Int. J. Nanomed. 7 (2012) 3667-3677, https://doi.org/10.2147/IJN.S30428.

[349] X.-Q. Luo, J.-W. Zhong, S.-Y. Qiu, M. Zhi, L.-Q. Yang, Y.-L. Zhou, F.-X. Zhou, P.-C. Yang, D.-B. Liu, L.-H. Mo, A20-OVA nanoparticles inhibit allergic asthma in a murine model, Inflammation 43 (3) (2020) 953-961, https://doi.org/10.1007/s10753-020-01181-5.

[350] S. Chakraborty, I. Ehsan, B. Mukherjee, L. Mondal, S. Roy, K.D. Saha, B. Paul, M. C. Debnath, T. Bera, Therapeutic potential of andrographolide-loaded nanoparticles on a murine asthma model, Nanomed. Nanotechnol. Biol. Med. 20 (2019) 102006, https://doi.org/10.1016/j.nano.2019.04.009.

[351] D. Wang, E. Mehrabi Nasab, S.S. Athari, Study effect of Baicalein encapsulated/ loaded Chitosan-nanoparticle on allergic Asthma pathology in mouse model, Saudi J. Biol. Sci. 28 (8) (2021) 4311-4317, https://doi.org/10.1016/j.sjbs.2021.04.009.

[352] A.J. Omlor, D.D. Le, J. Schlicker, M. Hannig, R. Ewen, S. Heck, C. Herr, A. Kraegeloh, C. Hein, R. Kautenburger, G. Kickelbick, R. Bals, J. Nguyen, Q. T. Dinh, Local effects on airway inflammation and systemic uptake of 5 nm PEGylated and citrated gold nanoparticles in asthmatic mice, Small 13 (10) (2017) 1603070, https://doi.org/10.1002/smll.201603070.

[353] M.F. Serra, A.C. Cotias, A.S. Pimentel, A.C.S.d. Arantes, A.L.A. Pires, M. Lanzetti, J.M. Hickmann, E. Barreto, V.F. Carvalho, P.M.R.e. Silva, R.S.B. Cordeiro, M. A. Martins, Gold nanoparticles inhibit steroid-insensitive asthma in mice preserving histone deacetylase 2 and NRF2 pathways, Antioxidants 11 (2022) 1659, https://doi.org/10.3391/antiox11091659.

[354] R. Halwani, A. Sultana Shaik, E. Ratemi, S. Afzal, R. Kenana, S. Al-Muhsen, A. Al Faraj, A novel anti-IL4Rα nanoparticle efficiently controls lung inflammation during asthma, Exp. Mol. Med. 48 (10) (2016) e262, https://doi.org/10.1038/emb.2016.89.

[355] N. Vij, T. Min, M. Bodas, A. Gorde, I. Roy, Neutrophil targeted nano-drug delivery system for chronic obstructive lung diseases, Nanomed. Nanotechnol. Biol. Med. 12 (8) (2016) 2415-2427, https://doi.org/10.1016/j.nano.2016.06.008.

[356] A. Al Faraj, A.S. Shaik, S. Afzal, B. Al Sayed, R. Halwani, MR imaging and targeting of a specific alveolar macrophage subpopulation in LPS-induced COPD animal model using antibody-conjugated magnetic nanoparticles, Int. J. Nanomed. 9 (2014) 1491-1503, https://doi.org/10.2147/IJN.S59394.

[357] V. De Leo, S. Ruscigno, A. Trapani, S. Di Gioia, F. Milano, D. Mandracchia, R. Comparelli, S. Castellani, A. Agostiano, G. Trapani, L. Catucci, M. Conese, Preparation of drug-loaded small unilamellar liposomes and evaluation of their potential for the treatment of chronic respiratory diseases, Int. J. Pharm. 545 (1) (2018) 378-388, https://doi.org/10.1016/j.ijpharm.2018.04.030.

[358] E.F. Craparo, M. Cabibbo, C. Scialabba, L. Casula, F. Lai, G. Cavallaro, Rapamycin-based inhaled therapy for potential treatment of COPD-related inflammation: production and characterization of aerosolizable nano into micro (NiM) particles, Biomater. Sci. 12 (2) (2024) 387-401, https://doi.org/10.1039/d3bm01210g.

[359] M.S. Cartiera, E.C. Ferreira, C. Caputo, M.E. Egan, M.J. Caplan, W.M. Saltzman, Partial correction of cystic fibrosis defects with PLGA nanoparticles encapsulating curcumin, Mol. Pharm. 7 (1) (2010) 86-93, https://doi.org/10.1021/mp900138a.

[360] A. Mukherjee, K.D. MacDonald, J. Kim, M.I. Henderson, Y. Eygeris, G. Sahay, Engineered mutant α-EnaC subunit mRNA delivered by lipid nanoparticles reduces amiloride currents in cystic fibrosis-based cell and mice models, Sci. Adv. 6 (47) (2020) eabc5911, https://doi.org/10.1126/sciadv.abc5911.

[361] O.B. Garbuzenko, N. Kbah, A. Kuzmov, N. Pogrebnyak, V. Pozharov, T. Minko, Inhalation treatment of cystic fibrosis with lumacaftor and ivacaftor co-delivered by nanostructured lipid carriers, J. Control. Release 296 (2019) 225-231, https://doi.org/10.1016/j.jconrel.2019.01.025.

[362] E.F. Craparo, M. Cabibbo, C. Scialabba, O. Laselva, V. Daniello, S. Di Gioia, M. Conese, G. Cavallaro, Lung disease management by iloprost-loaded nanoparticles to address hyperinflammation associated with cystic fibrosis, ACS Appl. Nano Mater. 7 (12) (2024) 14077-14089, https://doi.org/10.1021/acsnanm.4c01379.

[363] R. Kaur, T.B. Shaikh, H. Priya Sripadi, M. Kuncha, U.V.R. Vijaya Sarathi, H. Kulhari, S. Balaji Andugulapati, R. Sistla, Tintedanib solid lipid nanoparticles improve oral bioavailability and ameliorate pulmonary fibrosis in vitro and in vivo models, Int. J. Pharm. 649 (2024) 123644, https://doi.org/10.1016/j.ijpharm.2023.123644.

[364] Y. Liu, J. Liu, A. Quimbo, F. Xia, J. Yao, J.P. Clamme, S. Zabludoff, J. Zhang, W. Ying, Anti-HSP47 siRNA lipid nanoparticle ND-L02-s0201 reverses interstitial pulmonary fibrosis in preclinical rat models, ERJ Open Res. 7 (2) (2021) 733-2020, https://doi.org/10.1183/23120541.00733-2020.

[365] T.J. Torphy, L. Li, D.E. Griswold, Monoclonal antibodies as a strategy for pulmonary diseases, Curr. Opin. Pharmacol. 1 (3) (2001) 265-271, https://doi.org/10.1016/S1471-4892(01)00047-9.

[366] G. Desoubeaux, J.M. Reichert, M. Sleeman, K.L. Reckamp, B. Ryffel, J. P. Adamczewski, T.D. Sweeney, R. Vanbever, P. Diot, C.A. Owen, C. Page, S. Lerondel, A. Le Pape, N. Heuze-Vourc'h, Therapeutic monoclonal antibodies for respiratory diseases: current challenges and perspectives, March 31 - April 1, 2016, Tours, France, mAbs 8 (6) (2016) 999-1009, https://doi.org/10.1080/19420862.2016.1196521.

[367] A.P. Laddha, Y.A. Kulkarni, VEGF and FGF-2: promising targets for the treatment of respiratory disorders, Respir. Med. 156 (2019) 33-46, https://doi.org/10.1016/j.rmed.2019.08.003.

[368] D. Ribatti, T. Annese, S. Ruggieri, R. Tamma, E. Crivellato, Limitations of anti-angiogenic treatment of tumors, Translational Oncology 12 (7) (2019) 981-986, https://doi.org/10.1016/j.tranon.2019.04.022.

[369] L. Richeldi, E.R. Fernández Pérez, U. Costabel, C. Albera, D.J. Lederer, K. R. Flaherty, N. Ettinger, R. Perez, M.B. Scholand, J. Goldin, K.H. Peony Yu, T. Neff, S. Porter, M. Zhong, E. Gorina, E. Kouchakji, G. Raghu, Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial, Lancet Respir. Med. 8 (1) (2020) 25-33, https://doi.org/10.1016/s2213-2600(19)30262-0.

[370] A.I. Papaioannou, K. Kostikas, P. Kollia, K.I. Gourgoulianis, Clinical implications for vascular endothelial growth factor in the lung: friend or foe? Respir. Res. 7 (1) (2006) 128, https://doi.org/10.1186/1465-9921-7-128.